Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
Current SymbolNASDAQ:CRON
Previous Symbol
CUSIPN/A
Phone212-590-9070
Debt
Debt-to-Equity RatioN/A
Current Ratio9.03
Quick Ratio6.85
Price-To-Earnings
Trailing P/E Ratio1,272.00
Forward P/E Ratio-318.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.15 million
Price / Sales715.47
Cash Flow$0.0188 per share
Price / Cash Flow676.81
Book Value$0.47 per share
Price / Book27.06
Profitability
EPS (Most Recent Fiscal Year)$0.01
Net Income$1.92 million
Net Margins-45.72%
Return on Equity-3.22%
Return on Assets-3.02%
Miscellaneous
Employees148
Outstanding Shares177,180,000
Market Cap$2.25 billion
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
How were Cronos Group's earnings last quarter?
Cronos Group Inc (NASDAQ:CRON) posted its earnings results on Tuesday, November, 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The firm had revenue of $3.76 million for the quarter, compared to analyst estimates of $3.56 million. Cronos Group had a negative net margin of 45.72% and a negative return on equity of 3.22%. Cronos Group's revenue for the quarter was up 187.0% on a year-over-year basis. View Cronos Group's Earnings History.
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
3 Wall Street analysts have issued 1 year price objectives for Cronos Group's stock. Their forecasts range from $9.00 to $9.00. On average, they expect Cronos Group's stock price to reach $9.00 in the next year. This suggests that the stock has a possible downside of 29.2%. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
Press coverage about CRON stock has trended somewhat positive on Sunday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cronos Group earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the near future.
Are investors shorting Cronos Group?
Cronos Group saw a increase in short interest in November. As of November 15th, there was short interest totalling 28,682,369 shares, an increase of 4.6% from the October 31st total of 30,054,099 shares. Based on an average trading volume of 9,597,443 shares, the short-interest ratio is presently 3.0 days. View Cronos Group's Current Options Chain.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Canopy Growth (CGC), Aurora Cannabis Inc (TSE) (ACB), STADA Arzneimit/AKT o.N. (STDAF), USANA Health Sciences (USNA), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Pharmacyte Biotech (PMCB), Mannatech (MTEX), GLG Life Tech (GLGLF), Cyanotech (CYAN), FitLife Brands (FTLF) and Tauriga Sciences (TAUG).
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. William Hilson, Chief Financial Officer
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, VP of Bus. Devel.
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Morgan Stanley (0.47%), Gerber Kawasaki Wealth & Investment Management (0.12%), Essex Investment Management Co. LLC (0.08%), Wedbush Securities Inc. (0.07%), Commonwealth Equity Services LLC (0.05%) and Quantbot Technologies LP (0.04%).
Which major investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Lourd Capital LLC and Tower Research Capital LLC TRC .
Which major investors are buying Cronos Group stock?
CRON stock was acquired by a variety of institutional investors in the last quarter, including Gerber Kawasaki Wealth & Investment Management, Essex Investment Management Co. LLC, Wedbush Securities Inc., Morgan Stanley, MML Investors Services LLC, Quantbot Technologies LP, USA Mutuals Advisors Inc. and First Republic Investment Management Inc..
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $12.72.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $2.25 billion and generates $3.15 million in revenue each year. The company earns $1.92 million in net income (profit) each year or $0.01 on an earnings per share basis. Cronos Group employs 148 workers across the globe.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
